tiprankstipranks
Trending News
More News >
Medlive Technology Co., Ltd. (HK:2192)
:2192
Hong Kong Market

Medlive Technology Co., Ltd. (2192) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Medlive Technology Co., Ltd.

(2192)

Rating:75Outperform
Price Target:
HK$16.50
▲(15.38%Upside)
Medlive Technology Co., Ltd. shows strong financial performance, which is the primary driver of the stock's score. Technical indicators suggest potential for growth, though momentum is not strongly bullish. Valuation appears high, which could limit price appreciation, but the dividend yield offers some compensation.

Medlive Technology Co., Ltd. (2192) vs. iShares MSCI Hong Kong ETF (EWH)

Medlive Technology Co., Ltd. Business Overview & Revenue Model

Company DescriptionMedlive Technology Co., Ltd. (2192) is a technology-driven company that specializes in providing healthcare information services. The company operates primarily in the medical and healthcare sectors, offering a comprehensive platform that includes medical knowledge databases, online medical education, and other professional medical services to healthcare professionals and institutions.
How the Company Makes MoneyMedlive Technology Co., Ltd. generates revenue through various streams, primarily by offering subscription-based access to its comprehensive medical knowledge databases and online educational content. The company also earns income through partnerships with pharmaceutical companies and healthcare institutions, which may involve providing targeted advertising and promotional services. Additionally, Medlive may receive fees for offering tailored solutions and consulting services to its clients in the healthcare industry.

Medlive Technology Co., Ltd. Financial Statement Overview

Summary
Medlive Technology Co., Ltd. demonstrates robust financial performance with strong revenue growth, stable gross and net profit margins, and a solid balance sheet with low leverage. The company also maintains healthy cash flows, despite some variability in investment activities.
Income Statement
85
Very Positive
Medlive Technology Co., Ltd. demonstrates robust revenue growth, with Total Revenue increasing from 2019 to 2024. The Gross Profit Margin and Net Profit Margin have remained strong, reflecting stable and efficient cost management. Despite a decline in EBIT Margin from previous years, the EBITDA Margin remains healthy, indicating strong operational performance.
Balance Sheet
90
Very Positive
The company's Balance Sheet is solid with a high Equity Ratio, suggesting financial stability and low reliance on debt. The Debt-to-Equity Ratio is very low, indicative of minimal financial leverage. Return on Equity has shown a positive trend, highlighting effective use of shareholder funds.
Cash Flow
80
Positive
Cash flow analysis reveals consistent Free Cash Flow generation, with positive growth over time. The Operating Cash Flow to Net Income Ratio indicates strong cash-generating capability. However, fluctuations in Investing Cash Flow suggest potential volatility in investment activities.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue558.46M412.00M314.05M284.44M213.53M
Gross Profit327.22M251.34M212.74M200.73M156.24M
EBITDA121.35M262.86M144.56M76.61M110.37M
Net Income315.15M242.30M117.32M40.62M85.20M
Balance Sheet
Total Assets5.11B4.89B4.60B4.12B227.06M
Cash, Cash Equivalents and Short-Term Investments4.15B4.40B4.22B3.91B147.09M
Total Debt22.63M8.19M11.26M13.17M12.07M
Total Liabilities253.56M248.61M171.31M143.37M75.64M
Stockholders Equity4.80B4.60B4.40B3.95B151.41M
Cash Flow
Free Cash Flow87.44M69.34M69.70M42.47M110.42M
Operating Cash Flow108.32M101.87M77.19M44.43M111.05M
Investing Cash Flow111.02M-634.95M-3.59B-50.54M13.00K
Financing Cash Flow-197.89M-133.13M-22.38M3.79B-2.83M

Medlive Technology Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price14.30
Price Trends
50DMA
13.42
Positive
100DMA
13.11
Positive
200DMA
10.96
Positive
Market Momentum
MACD
0.30
Positive
RSI
47.25
Neutral
STOCH
14.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Positive. The current price of 14.3 is below the 20-day moving average (MA) of 15.37, above the 50-day MA of 13.42, and above the 200-day MA of 10.96, indicating a neutral trend. The MACD of 0.30 indicates Positive momentum. The RSI at 47.25 is Neutral, neither overbought nor oversold. The STOCH value of 14.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2192.

Medlive Technology Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
HK$3.24B10.597.40%4.59%0.67%-1.75%
78
Outperform
HK$57.88B7.589.19%3.98%-3.94%-23.48%
75
Outperform
HK$10.48B30.516.72%2.08%33.41%26.81%
66
Neutral
$65.29B9.366.08%2.95%3.27%12.87%
60
Neutral
HK$15.31B5.72-7.43%4.61%11.60%-21.06%
45
Neutral
HK$701.35M-31.49%-7.28%-46.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2192
Medlive Technology Co., Ltd.
14.36
7.54
110.56%
HK:1931
IVD Medical Holding Limited
2.05
1.18
135.63%
HK:9955
ClouDr Group Limited
1.09
-0.70
-39.11%
HK:1099
Sinopharm Group Co
18.52
-1.14
-5.81%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.86
0.63
5.65%

Medlive Technology Co., Ltd. Corporate Events

Medlive Technology Updates Nomination Committee Terms
Jun 30, 2025

Medlive Technology Co., Ltd. has updated the terms of reference for its Nomination Committee, effective from June 30, 2025. The committee, which will consist of at least three directors with a majority being independent non-executive directors, is tasked with reviewing the board’s structure and composition annually. This move aims to ensure the board’s alignment with the company’s corporate strategy and enhance its governance by selecting qualified individuals for directorships.

Medlive Technology Co., Ltd. Successfully Concludes Annual General Meeting with Key Resolutions Passed
May 8, 2025

Medlive Technology Co., Ltd. held its Annual General Meeting on May 8, 2025, where all proposed resolutions were approved by shareholders. Key outcomes included the re-election of directors, the declaration of a final dividend for 2024, and the approval of mandates for share repurchase and issuance, indicating strong shareholder support and strategic direction for the company’s future operations.

Medlive Technology Announces 2025 AGM with Key Resolutions
Apr 14, 2025

Medlive Technology Co., Ltd. has announced its upcoming annual general meeting scheduled for May 8, 2025, where key resolutions will be considered. These include the approval of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks shareholder approval for share repurchase and issuance mandates, potentially impacting its capital structure and market operations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025